Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: A descriptive monocentric study

Dermatol Ther. 2020 Jan;33(1):e13182. doi: 10.1111/dth.13182. Epub 2019 Dec 18.


The objective of our study was to describe the effectiveness and safety of oral dutasteride (OD) for male androgenetic alopecia in real clinical practice. A retrospective, monocentric, and descriptive study was designed. Male patients with androgenetic alopecia that had received OD for at least 12 months were included. Three or less capsules of 0.5 mg per week were considered low doses. Therapeutic response was assessed by comparison of pre- and post-treatment (at month 12) clinical images by three independent dermatologists with expertise in hair disorders, using a four-point scale (worsening, stabilization, mild improvement or marked improvement). In all, 307 patients with a mean age of 35.3 years (range 18-79) were included. Eight patients (2.6%) required the discontinuation of the drug due to decreased libido (n = 4), gynecomastia (n = 2), mood disorder (n = 1) and erectile dysfunction (n = 1). All these AE resolved after stopping the medication. No AE were detected in patients receiving low doses of OD. The effectiveness was evaluated in the subgroup of 42 patients (13.7%) who received OD in monotherapy: 38 patients improved (90%), 10 of them (23.8%) presenting a marked improvement, 4 patients (9.5%) were stable and none patient worsened. In conclusion, OD is an effective treatment for male androgenetic alopecia in real clinical practice, presenting a good safety profile, especially at lower doses.

Keywords: Dutasteride; alopecia; androgenetic alopecia; baldness; five-alpha reductase; hair loss.

Publication types

  • Letter

MeSH terms

  • 5-alpha Reductase Inhibitors / administration & dosage*
  • 5-alpha Reductase Inhibitors / adverse effects
  • Administration, Oral
  • Adolescent
  • Adult
  • Aged
  • Alopecia / drug therapy*
  • Dutasteride / administration & dosage*
  • Dutasteride / adverse effects
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Treatment Outcome
  • Young Adult


  • 5-alpha Reductase Inhibitors
  • Dutasteride